ReviewPolymer science & technology (Washington, D.C.)2025
Bacterial Systems as a Precision Delivery Platform of Therapeutic Peptides for Cancer Therapy.
Review in Polymer science & technology (Washington, D.C.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Bacterial-based cancer therapy: mechanisms and therapeutic advances.Molecular biomedicine · 2026Review
- Engineered Escherichia coli as a microbial cell factory for intracellular protein delivery: strains, vectors, mechanisms, and therapeutic applications.Microbial cell factories · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, peptide-based therapies have gained remarkable attention as promising tools for cancer treatment, offering notable advantages in specificity, modifiability, and reduced systemic toxicity. Various peptide classesincluding cell-penetrating, tumor-homing, pro-apoptotic, and immune-modulating peptideshave shown appreciable efficacy in selectively targeting cancer cells and modulating immune responses against tumors. Despite this potential, peptide therapies face significant challenges, such as susceptibility to rapid degradation, limited bioavailability, and inadequate accumulation within tumors. To address these issues, bacterial systems have emerged as innovative peptide delivery platforms, improving peptide stability, enhancing localized concentrations, and enabling controlled release directly at tumor sites. This review explores the synergistic potential of therapeutic peptides combined with bacterial delivery systems, with a focus on methods such as bacterial lysis for peptide release, secretion pathways, and peptide surface display. By harnessing the tumor-targeting properties and secretion capabilities of bacteria, these integrated approaches offer promising solutions to overcome the inherent limitations of peptide therapies, positioning them as advanced tools in precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.